GENNQ (Genesis Healthcare) Research & Development: $0 Mil (TTM As of Dec. 2020)


GENNQ Genesis Healthcare Inc GENNQ
12 GF Score
Price $0.00
View Full Analysis

What is Genesis Healthcare Research & Development?

Genesis Healthcare GENNQ -99.00% 12 Research & Development is $0 Mil as of Dec. 2020. GuruFocus rates GENNQ with a GF Score™ of 12/100.

Research & Development is the aggregate amount of research and development expenses during the year. Genesis Healthcare's Research & Development for the three months ended in Dec. 2020 was $0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2020 was $0 Mil.

Genesis Healthcare  (OTCPK:GENNQ) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Genesis Healthcare Research & Development Related Terms

Genesis Healthcare Research & Development Historical Data

* Premium members only.

The historical data trend for Genesis Healthcare's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genesis Healthcare Research & Development Chart

Genesis Healthcare Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Genesis Healthcare Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
GENNQ
12GF Score
Genesis Healthcare Inc GENNQ
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genesis Healthcare Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0 Mil mean?
Genesis Healthcare (GENNQ) has a Research & Development of $0 Mil as of Dec. 2020. Research and development expense is the total cost for research and development activities. View historical data on Genesis Healthcare and its competitors.
Is Genesis Healthcare's Research & Development too high?
Genesis Healthcare's current Research & Development is $0 Mil. Overall, Genesis Healthcare has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Genesis Healthcare's Research & Development compare to AIH and JYNT?
Genesis Healthcare's Research & Development of $0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Genesis Healthcare and its competitors. Genesis Healthcare's current Research & Development is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genesis Healthcare stock overvalued right now?
Genesis Healthcare (GENNQ) has a current Research & Development of $0 Mil. The current Research & Development is $0 Mil. Genesis Healthcare's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Genesis Healthcare (GENNQ), the current Research & Development is $0 Mil as of Dec. 2020. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genesis Healthcare Business Description

Address 101 East State Street, Kennett Square, PA, USA, 19348
Genesis Healthcare Inc is a post-acute care provider in the United States. It focuses on the medical and physical issues facing elderly patients and is provided by the employees of skilled nursing facilities, assisted/senior living communities, integrated and third-party rehabilitation therapy business. The company has three operating segments. The inpatient services segment include the operation of skilled nursing facilities and assisted/senior living facilities; rehabilitation therapy segment services include integrated and third-party rehabilitation and respiratory therapy services; and all other services. The majority of its revenue is generated from its skilled nursing facilities of the inpatient services segment.
12GF Score

Get the complete analysis for GENNQ

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price